Picture courtesy The Indian Express
Pune: Serum Institute of India (SII) has sought emergency use authorisation (EUA) for its COVID-19 vaccine Covovax for the 12-17 age group.
Prakash Kumar Singh, Director, Government and Regulatory Affairs at SII, stated in the application that data from two studies on 2,707 children aged 12 to 17 years show that Covovax is highly efficacious, immunogenic, safe and well-tolerated in this age group, The Indian Express reported quoting official sources.
The Drugs Controller General Of India (DCGI) has already approved Covovax for emergency use among adults.
Covovax is produced in India by Pune-based Serum Institute through technology transfer from American biotechnology company Novavax.
Earlier today, DCGI granted emergency use approval to Biological E’s indigenous vaccine Corbevax for children aged 12 to 17 years.
Currently, only those in the 15-17 year age group are being inoculated in India.
Cuttack: The Cuttack City Police announced restrictions on movement of vehicular traffic during immersion procession…
Cuttack: In a major achievement for police, a counterfeit currency note racket has been busted…
Bhubaneswar: Odisha Vigilance officials on Tuesday conducted simultaneous raids at eight places linked to Ramesh…
Karnal/Srinagar: With counting of votes still underway for the assembly elections in Haryana and Jammu…
Bhubaneswar: The Commissionerate Police on Monday announced the restrictions on movement of vehicular traffic during…
Mumbai: Reel life hero Ranveer Singh turned saviour for a little girl who had got…
Mumbai: Karan Johar’s Dharma Productions has decided to stop pre-release screenings of their movies, the…
Bhubaneswar: In order to ensure smooth movement of vehicles and maintain law and order during…